Clinical Trials Using Humanized Monoclonal Antibody 3F8
Clinical trials are research studies that involve people. The clinical trials on this list are studying Humanized Monoclonal Antibody 3F8. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
Humanized Monoclonal Antibody 3F8 and Sargramostim in Treating Patients with Recurrent Osteosarcoma
This phase II trial studies how well humanized monoclonal antibody 3F8 (Hu3F8) and sargramostim work in treating patients with bone cancer (osteosarcoma) that has come back (recurrent). Humanized monoclonal antibody 3F8 is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Colony-stimulating factors, such as sargramostim, may increase the number of granulocytes (kinds of white blood cells that are able to kill cancer cells). Sargramostim increases the number of other kinds of white blood cells that may help attack tumor cells. Sargramostim may also make humanized monoclonal antibody 3F8 more effective against osteosarcoma. Giving humanized monoclonal antibody 3F8 together with sargramostim may be an effective treatment for patients with osteosarcoma.
Location: 3 locations
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and / or Bone Marrow
Children and adults diagnosed with high-risk neuroblastoma patients with primary refractory disease or incomplete response to salvage treatment in bone and / or bone marrow will be treated for up to 101 weeks with naxitamab and granulocyte-macrophage colony stimulating factor (GM-CSF). Patients will be followed for up to five years after first dose. Naxitamab, also known as hu3F8 is a humanised monoclonal antibody targeting GD2
Location: 2 locations